New US Study Reveals Key Reasons why Millions of People with Obesity are not Receiving Adequate Care
New US Study Reveals Key Reasons why Millions of People with Obesity are not Receiving Adequate Care
PR70793
WASHINGTON, Oct.. 31, 2017 / PRNewswire=KYODO JBN/ -
- Despite increasing recognition of obesity as a disease, many barriers
to effective care remain
Few of the more than 90 million Americans with obesity are seeking and
receiving long-term obesity care, according to new data from the Awareness,
Care and Treatment In Obesity Management (ACTION) Study published today in
Obesity,[2] the official journal of The Obesity Society. Among the notable
findings is that of the 71% of people with obesity who say they have spoken
with a healthcare professional (HCP) about their weight in the past 5 years,
only 55% report having been given a diagnosis of obesity and less than a
quarter (24%) were offered follow-up care for this disease.[2] ACTION data will
be presented through poster and symposia forums at ObesityWeek, currently in
progress in Washington DC.
Designed to identify key barriers to care from the perspective of people
with obesity, HCPs and employers, the results of the ACTION Study, according to
multi-disciplinary steering committee members who led the initiative, can guide
collaborative action to improve care, education and support for those who live
with obesity.
"We in the healthcare community must ask why this epidemic is not being
diagnosed and treated with the same urgency and focus as any other serious
diseases?" said Dr Lee Kaplan, director of the Obesity, Metabolism and
Nutrition Institute at Massachusetts General Hospital, ACTION steering
committee member and lead author of the study. "We need to fundamentally
rethink obesity so that the public and healthcare community understand more
about the biology, chronicity and overall health impact of this disease. Real
progress can be achieved if we can overcome the entrenched mindsets that
generate the barriers revealed by this study."
Conducted with more than 3,500 participants spanning all three target
groups, the ACTION Study reveals five key barriers to comprehensive care:
- people with obesity engage in several serious weight loss attempts but
only a few are able to maintain the achieved weight loss;
- despite recognition of obesity as a disease, most people with obesity
consider weight loss to be completely their own responsibility, which
may prevent them from seeking help from their HCP;
- nearly half of people with obesity have not been given a formal
diagnosis of obesity;
- the patient-provider dialogue about weight management is insufficient
with limited follow-up; and
- employer wellness programmes are not meeting the needs of people with
obesity.
"The barriers identified in the study highlight opportunities to bridge
gaps in understanding to facilitate true collaboration among all stakeholders,"
said study co-author and ACTION steering committee member Dr Angela Golden,
owner of a specialty obesity practice in Arizona. "Only by bridging these gaps
will obesity care become integral to standard practice, whether in a healthcare
or employment setting, and people with obesity will have the care and support
needed to effectively treat their obesity."
About ACTION
The "Awareness, Care and Treatment In Obesity Management" (ACTION) Study is the
first US nationwide study to investigate barriers to obesity management from
the perspective of people with obesity, healthcare professionals and employers.
In addition, the study aims to generate insights to guide collaborative action
to improve obesity care, education and support. Sponsored by Novo Nordisk, the
ACTION Study was led by a multi-disciplinary steering committee comprised of
representatives from The Obesity Society, the Obesity
Action Coalition, and the Integrated Benefits Institute as well as obesity
experts in the fields of primary care, endocrinology, psychology and nursing.
The study involved more than 3,000 people with obesity, 600 healthcare
professionals, and 150 employers in the United States. To learn more about the
study, please visit: http://www.ACTIONStudy.com.
About obesity
Obesity is a disease[3],[4] that requires long-term management. It is
associated with many serious health consequences and decreased life
expectancy.[5],[6] Obesity-related comorbidities include type 2 diabetes, heart
disease, obstructive sleep apnoea (OSA) and certain types of cancer.[5],[7],[8]
It is a complex and multi-factorial disease that is influenced by
physiological, psychological, environmental, socio-economic and genetic
factors.[9]
The global increase in the prevalence of obesity is a public health issue
that has severe cost implications to healthcare systems. In 2014, 13% of
adults, or approximately 600 million adults, were living with obesity.[10]
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of
innovation and leadership in diabetes care. This heritage has given us
experience and capabilities that also enable us to help people defeat other
serious chronic conditions: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in
77 countries and markets its products in more than 165 countries. For more
information, visit: www.novonordisk.com [http://www.novonordisk.com ], Facebook
[http://www.facebook.com/novonordisk ], Twitter
[http://www.twitter.com/novonordisk ], LinkedIn
[http://www.linkedin.com/company/novo-nordisk ], YouTube
[http://www.youtube.com/novonordisk ]
References
1. Obesity and Overweight. Centers for Disease Control and Prevention.
Available at:
https://www.cdc.gov/nchs/fastats/obesity-overweight.htm. Last accessed: October
2017.
2. Kaplan L, Golden A, Jinnett K, et al. Perceptions of Barriers to
Effective Obesity Care: Results from the National ACTION Study. Obesity.
2017;DOI:10.1002/oby.22054.
3. American Medical Association. A.M.A Adopts New Policies on Second Day of
Voting at Annual Meeting. Obesity as a Disease. Available at:
. Last accessed: October 2017.
4. WHO. Obesity: Preventing and managing the global epidemic. Available at:
http://www.who.int/iris/handle/10665/42330. Last accessed: October 2017.
5. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities
related to obesity and overweight: a systematic review and meta-analysis. BMC
Public Health. 2009;9:1-20.
6. Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and
its consequences for life expectancy: a life-table analysis. Annals of Internal
Medicine. 2003;138:24-32.
7. Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea.
Endocrinology and Metabolism Clinics of North America. 2003;32:869-894.
8. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and
cause-specific mortality in 900 000 adults: collaborative analyses of 57
prospective studies. Lancet. 2009;373:1083-1096.
9. Wright SM, Aronne LJ. Causes of obesity. Abdominal Imaging.
2012;37:730-732.
10. World Health Organization. Obesity and Overweight Factsheet no. 311.
Available at:
http://www.who.int/mediacentre/factsheets/fs311/en. Last accessed: October
2017.
Further information
Media:
Katrine Sperling +45-4442-6718 krsp@novonordisk.com
Ken Inchausti (US) +1-609-786-8316 kiau@novonordisk.com
Investors:
Peter Hugreffe Ankersen +45-3075-9085 phak@novonordisk.com
Hanna Ögren +45-3079-8519 haoe@novonordisk.com
Anders Mikkelsen +45-3079-4461 armk@novonordisk.com
Christina Kjaer +45-3079-3009 cnje@novonordisk.com
Kasper Veje (US) +1-609-235-8567 kpvj@novonordisk.com
SOURCE: Novo Nordisk
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。